Received Jun 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | — | IM / RA |
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | 3E99M | IM / LA |
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | DD72H | RA |
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | 3E99M | LA |
could not lift right arm; Pain injection site; numbness, swelling and redness at injection site right arm; could not lift right arm; numbness, swelling and redness at injection site right arm; This non-serious case was reported by a other health professional via call center representative and described the occurrence of injection site pain in a 16-year-old female patient who received Men B NVS (Bexsero) (batch number DD72H) for prophylaxis. Co-suspect products included Men ACWY-CRM NVS (Menveo) (batch number 3E99M) for prophylaxis. On 24-APR-2025, the patient received Bexsero (right deltoid) and Menveo (left arm). On 24-APR-2025, several hours after receiving Bexsero and Menveo, the patient experienced injection site pain (Verbatim: Pain injection site), injection site numbness (Verbatim: numbness, swelling and redness at injection site right arm), injection site swelling (Verbatim: could not lift right arm) and injection site erythema (Verbatim: numbness, swelling and redness at injection site right arm). On 25-APR-2025, the patient experienced injected limb mobility decreased (Verbatim: could not lift right arm). The outcome of the injection site pain, injection site numbness, injection site swelling and injection site erythema were resolved and the outcome of the injected limb mobility decreased was unknown. It was unknown if the reporter considered the injection site pain, injection site numbness, injection site swelling, injection site erythema and injected limb mobility decreased to be related to Bexsero, Bexsero Pre-Filled Syringe Device and Menveo. It was unknown if the company considered the injection site pain, injection site numbness, injection site swelling, injection site erythema and injected limb mobility decreased to be related to Bexsero, Bexsero Pre-Filled Syringe Device and Menveo. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 28-MAY-2025 The reporter reported that the patient had Bexsero in right arm and Menveo in left arm, on 24th April 2025, a few hours later, she experienced right arm, pain, redness, swelling and numbness at injection site. The next day she could not lift right arm. This case US2025066669 reported by same reporter.; Sender's Comments: US-GSK-US2025066669:1 of 2 report